BioNTech company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biontech.de

Founded Year

2008

Stage

PIPE | IPO

Total Raised

$771.5M

Market Cap

30.05B

Stock Price

132.44

About BioNTech

BioNTech is developing personalized immunotherapies to help the treatment of people with cancer and other debilitating diseases.

BioNTech Headquarter Location

An der Goldgrube 12

Mainz, 55131,

Germany

+49-6131-9084-0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing BioNTech

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BioNTech in 4 CB Insights research briefs, most recently on Apr 19, 2021.

Expert Collections containing BioNTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioNTech is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BioNTech Patents

BioNTech has filed 166 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/18/2019

5/31/2022

Immune system, Immunology, Clusters of differentiation, Transcription factors, Proteins

Grant

Application Date

6/18/2019

Grant Date

5/31/2022

Title

Related Topics

Immune system, Immunology, Clusters of differentiation, Transcription factors, Proteins

Status

Grant

Latest BioNTech News

Rwanda: the construction of the first mRNA vaccine factory in Africa kicks off

Jun 24, 2022

Paul Kagame, president of Rwanda (center L) and Ugur Sahin CEO of BioNtech (R) mark the beginning of the construction of a mRNA vaccine factory, Kigali, 23 June 2022. -   Copyright © africanews Rwandan president Paul Kagame and BioNtech's CEO Ugur Sahin launched on Thursday, the construction of a messenger RNA vaccine factory in Kigali. It is Africa's first of three planned projects on the continent and aims to produce treatments against Covid-19 and other diseases by early 2024. "BioNTech is researching and developing vaccines and medicines to prevent malaria, tuberculosis and HIV. These deseases are major causes of mortality on the African continent. We've partnerd with the Bill and Melinda Gates Foundation to develop the tuberculosis and HIV vaccines and we are developing malaria vaccines. ", said Ugur Sahin, BioNTech's CEO. Paul Kagama called the project "grounbreaking" and said his country worked to attract biopharmaceutical researchers in the manufacturing sector. Production will include vaccines against Covid, but also pioneering treatments currently in development against malaria, tuberculosis and HIV, diseases that are ravaging Africa. Human trials of a BioNTech malaria vaccine using mRNA technology are expected to begin in late 2022. Africa is the world's least vaccinated continent against Covid-19. Less than 20% of its 1.2 billion population have received two doses of vaccine. Related articles

BioNTech Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioNTech Rank

  • When was BioNTech founded?

    BioNTech was founded in 2008.

  • Where is BioNTech's headquarters?

    BioNTech's headquarters is located at An der Goldgrube 12, Mainz.

  • What is BioNTech's latest funding round?

    BioNTech's latest funding round is PIPE.

  • How much did BioNTech raise?

    BioNTech raised a total of $771.5M.

  • Who are the investors of BioNTech?

    Investors of BioNTech include Temasek, Bill & Melinda Gates Foundation, Sanofi, Pfizer, Invus Group and 8 more.

  • Who are BioNTech's competitors?

    Competitors of BioNTech include HDT Bio.

You May Also Like

H
HDT Bio

HDT Bio is a biopharmaceutical company formed to address critical unmet needs to treat cancers and infectious diseases. It is based in Seattle, Washington.

Moderna Therapeutics Logo
Moderna Therapeutics

Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.